{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:14:39Z","timestamp":1771488879156,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Targeted therapies are a standard of care for first-line treatment of Anaplastic lymphoma kinase (<jats:italic>ALK<\/jats:italic>)-rearranged non small cell lung cancer (NSCLC). Giving the rapid pace of drug discovery and development in this area, reporting of adverse effects of ALK inhibitors is crucial. Here, we report a case of osteitis induced by an ALK inhibitor mimicking bone metastasis, a previously undescribed side effect of crizotinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 31-year-old woman with stage IV<jats:italic>ALK<\/jats:italic>-rearranged NSCLC presented with back pain after 3\u2009months of crizotinib treatment. Diagnostic work-up showed osteitis on the 4th and 5th thoracic vertebrae, anterior soft tissue infiltration and epiduritis, without any sign of infection. Spinal cord decompression, histological removal and osteosynthesis were performed. Histologic examination showed necrosis with abundant peripheral neutrophils, no microorganism nor malignant cell. Symptoms and Computarized Tomography-abnormalities rapidly diseappeared after crizotinib withdrawal and did not recur after ceritinib onset.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This is the first report of crizotinib-induced osteitis. Crizotinib differs from other ALK inhibitors as it targets other kinases as well, which may have been responsible for the osteitis. Crizotinib can induce rapidly extensive osteitis, which can mimic tumor progression.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-019-6486-3","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T15:02:51Z","timestamp":1578322971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-7303","authenticated-orcid":false,"given":"F.","family":"Guisier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Piton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bellefleur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Delberghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Avenel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Angot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Vittecoq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ould-Slimane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Morisse-Pradier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Salaun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Thiberville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,6]]},"reference":[{"issue":"7153","key":"6486_CR1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561\u20136.","journal-title":"Nature."},{"issue":"25","key":"6486_CR2","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Kim D-W, Nakagawa K, Seto T, Crino L, Ahn M-J, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385\u201394.","journal-title":"N Engl J Med"},{"issue":"10089","key":"6486_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","volume":"390","author":"T Hida","year":"2017","unstructured":"Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390(10089):29\u201339.","journal-title":"Lancet"},{"issue":"9","key":"6486_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung Cancer. N Engl J Med. 2017;377(9):829\u201338.","journal-title":"N Engl J Med"},{"issue":"10072","key":"6486_CR5","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","volume":"389","author":"J-C Soria","year":"2017","unstructured":"Soria J-C, Tan DSW, Chiari R, Wu Y-L, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917\u201329.","journal-title":"Lancet"},{"issue":"21","key":"6486_CR6","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","volume":"379","author":"DR Camidge","year":"2018","unstructured":"Camidge DR, Kim HR, Ahn M-J, Yang JC-H, Han J-Y, Lee J-S, et al. Brigatinib versus Crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379(21):2027\u201339.","journal-title":"N Engl J Med"},{"issue":"9","key":"6486_CR7","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.1158\/0008-5472.CAN-06-4443","volume":"67","author":"HY Zou","year":"2007","unstructured":"Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, et al. An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007;67(9):4408\u201317.","journal-title":"Cancer Res"},{"issue":"30","key":"6486_CR8","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1200\/JCO.2017.74.6065","volume":"35","author":"N Hanna","year":"2017","unstructured":"Hanna N, Johnson D, Temin S, Baker SJ, Brahmer J, Ellis PM, et al. Systemic therapy for stage IV non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2017;35(30):3484\u2013515.","journal-title":"J Clin Oncol"},{"key":"6486_CR9","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","volume":"19","author":"BJ Solomon","year":"2018","unstructured":"Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19:1654\u201367.","journal-title":"Lancet Oncol"},{"key":"6486_CR10","doi-asserted-by":"crossref","unstructured":"Huber RM, Hansen KH, Paz-Ares Rodr\u00edguez L, West HL, et al. Brigatinib in Crizotinib-refractory ALK+ non-small cell lung Cancer: 2-year follow-up on systemic and intracranial outcomes in the phase 2 ALTA trial. J Thorac Oncol. 2019. (In Press).","DOI":"10.1016\/j.jtho.2019.11.004"},{"issue":"2","key":"6486_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.lungcan.2014.12.010","volume":"87","author":"F Cappuzzo","year":"2015","unstructured":"Cappuzzo F, Moro-Sibilot D, Gautschi O, Boleti E, Felip E, Groen HJM, et al. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus. Lung Cancer. 2015;87(2):89\u201395.","journal-title":"Lung Cancer"},{"issue":"3","key":"6486_CR12","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1097\/JTO.0b013e31827e2451","volume":"8","author":"N Srivastava","year":"2013","unstructured":"Srivastava N, VanderLaan PA, Kelly CP, Costa DB. Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer. J Thorac Oncol. 2013;8(3):e23\u20134.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"6486_CR13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jtho.2018.12.014","volume":"14","author":"JM Pacheco","year":"2019","unstructured":"Pacheco JM, Gao D, Smith D, Purcell T, Hancock M, Bunn P, et al. Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung Cancer. J Thorac Oncol. 2019;14(4):691\u2013700.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"6486_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1200\/JCO.2015.62.0138","volume":"34","author":"KL Johung","year":"2016","unstructured":"Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung Cancer and brain metastasis. J Clin Oncol. 2016;34(2):123\u20139.","journal-title":"J Clin Oncol"},{"key":"6486_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.lungcan.2017.01.010","volume":"106","author":"DF Halpenny","year":"2017","unstructured":"Halpenny DF, McEvoy S, Li A, Hayan S, Capanu M, Zheng J, et al. Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-incidence, radiological features and clinical characteristics. Lung Cancer. 2017;106:33\u20136.","journal-title":"Lung Cancer"},{"key":"6486_CR16","doi-asserted-by":"publisher","first-page":"bcr2015211556","DOI":"10.1136\/bcr-2015-211556","volume":"2015","author":"H Ishida","year":"2015","unstructured":"Ishida H, Ichikawa W, Sasaki Y. Crizotinib-induced pancreatic pseudocyst: a novel adverse event. BMJ Case Rep. 2015;2015:bcr2015211556.","journal-title":"BMJ Case Rep"},{"issue":"1","key":"6486_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5125\/jkaoms.2019.45.1.3","volume":"45","author":"AF Nifos\u00ec","year":"2019","unstructured":"Nifos\u00ec AF, Zuccarello M, Nifos\u00ec L, Hervas Saus V, Nifos\u00ec G. Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology. J Korean Assoc Oral Maxillofac Surg. 2019;45(1):3\u20138.","journal-title":"J Korean Assoc Oral Maxillofac Surg"},{"issue":"19","key":"6486_CR18","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.3390\/ijms20194925","volume":"20","author":"A Anesi","year":"2019","unstructured":"Anesi A, Generali L, Sandoni L, Pozzi S, Grande A. From osteoclast differentiation to osteonecrosis of the jaw: molecular and clinical insights. Int J Mol Sci. 2019;20(19):4925.","journal-title":"Int J Mol Sci"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6486-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6486-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6486-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T02:38:34Z","timestamp":1665369514000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6486-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,6]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6486"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6486-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,6]]},"assertion":[{"value":"8 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A written informed consent has been provided by the patient to have the case details and any accompanying images published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FG reports personal fees BMS, MSD\/MERCK US, ASTRA ZENECA, BOEHRINGER INGELHEIM and ROCHE, and non-financial support from BMS, BOEHRINGER INGELHEIM, CHUGAI and PFIZER, outside the submitted work.NP, MB, ND, GA, EA, OV, MOS, HMP, MS and LT have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}